Regulators need patient-centric approach to obesity drug reviews
This article was originally published in Scrip
Obesity-focused stakeholders are calling on regulators to take a more patient-centric approach when evaluating the benefits and risks of obesity drugs. The George Washington University (GWU) School of Public Health and Health Services has published Obesity drug outcome measures, a report detailing the consensus of findings from a stakeholder dialogue group, convened by the university, outlining a series of new approaches that should be considered by regulators when looking at obesity drugs.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.